Spero Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Spero Therapeutics, Inc. (SPRO) reported Increase Decrease In Operating Lease Liability of -$852.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- Spero Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$431.00K.
- Spero Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$421.00K.
- Spero Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$264.00K.
- Spero Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$345.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month |
|---|---|---|---|
| 2026-06-30 | -$431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$852.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$421.00K 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | -$264.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$609.00K derived: sum of 2 quarters · filed 2026-08-12 | -$946.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$345.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$682.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$337.00K 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | -$316.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$622.00K derived: sum of 2 quarters · filed 2025-11-13 | -$921.00K 10-Q · filed 2025-11-13 |
| 2024-06-30 | -$306.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$605.00K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | -$299.00K 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | -$280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$551.00K derived: sum of 2 quarters · filed 2024-11-14 | -$816.00K 10-Q · filed 2024-11-14 |
| 2023-06-30 | -$271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$536.00K 10-Q · filed 2024-08-05 | |
| 2023-03-31 | -$265.00K 10-Q · filed 2024-05-15 | ||
| 2022-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$194.00K derived: sum of 2 quarters · filed 2023-11-13 | -$434.00K 10-Q · filed 2023-11-13 |
| 2022-06-30 | -$94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$334.00K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | -$240.00K 10-Q · filed 2023-05-11 | ||
| 2021-09-30 | -$205.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$410.00K derived: sum of 2 quarters · filed 2022-11-14 | -$605.00K 10-Q · filed 2022-11-14 |
| 2021-06-30 | -$205.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$400.00K 10-Q · filed 2022-08-10 | |
| 2021-03-31 | -$195.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |